Agile therapeutics reports third-quarter 2019 financial results

Agile therapeutics reports third quarter 2019 financial results.q3 loss per share $0.08.q3 earnings per share estimate $-0.08 -- refinitiv ibes data.says cash expected to enable company to fund operations through end of q1 2020.says resubmitted twirla nda in q2 of 2019 and has been assigned a november 16, 2019 pdufa goal date.
AGRX Ratings Summary
AGRX Quant Ranking